T9450
Anti-Tau antibody, Mouse monoclonal
clone Tau46, purified from hybridoma cell culture
Synonym(s):
Anti-DDPAC, Anti-FTDP-17, Anti-MAPTL, Anti-MSTD, Anti-MTBT1, Anti-MTBT2, Anti-PPND, Anti-PPP1R103, Anti-TAU, Anti-tau-40
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
mouse
Quality Level
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
Tau46, monoclonal
form
buffered aqueous solution
species reactivity
bovine, rat, human, mouse
packaging
antibody small pack of 25 μL
concentration
~2 mg/mL
technique(s)
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
indirect ELISA: suitable
microarray: suitable
western blot: 0.5-1 μg/mL using mouse brain extract
isotype
IgG1
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... MAPT(4137)
mouse ... Mapt(17762)
rat ... Mapt(29477)
General description
Tau (τ), also known as MAPT (microtubule associated protein tau), is encoded by the gene mapped to human chromosome 17q21.3. It is highly expressed in neurons, but is most prominent in axons.
Tau is a family of microtubule-associated proteins thought to regulate the stability and organization of microtubules in neuronal cells. The tau protein family is derived from alternative mRNA splice variants that originate from a single gene, and result in mature proteins that vary in size from 352 to 441 amino acids (45 to 60 kDa). Tau loses microtubule-binding activity and aggregates into paired helical filaments (PHFs) in neurodegenerative disorders. PHFs are the basic structural components of neurofibrillary tangles (NFTs). NFT accumulation correlates with the clinical progression of Alzheimer′s disease. Phosphorylation can affect the functional properties of tau and hyperphosphorylation of tau may result in the loss of tau′s microtubule binding activity and the formation of the insoluble aggregates. Hyperphosphorylation and nonenzymatic glycosylation are posttranslational modifications detected in PHF-tau, and numerous sites of hyperphosphorylation of both normal and PHF-tau have been identified.
Specificity
Mouse monoclonal clone Tau46 anti-Tau antibody recognizes bovine, rat, human, and mouse Tau (approx. 45 to 60 kDa). The antibody recognizes a phosphorylation-independent epitope in amino acids 404-441 (human). The antibody recognizes all six isoforms of Tau and may cross react with MAP2 protein.
Immunogen
bovine Tau.
Application
Anti-Tau antibody, Mouse monoclonal has been used in western blotting.
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)
Western Blotting (1 paper)
Mouse monoclonal clone Tau46 anti-Tau antibody is useful in ELISA, immunoblotting, immunogold labeling, immunopreciptation as well as immunohistochemistry. It is used as a probe to determine the presence and roles of Tau protein in the regulation of the stability and organization of microtubules in neuronal cells.
Biochem/physiol Actions
Tau (τ) plays an essential role in the assembly and maintenance of microtubule structure. Deletion of tau (τ) results in developmental delay and learning disability. The gene expression is associated with the development of Alzheimer′s disease (AD). Genetic variation in τ gene increases the risk of susceptibility to the sporadic tauopathies, progressive supranuclear palsy (PSP) and corticobasal degeneration.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Jeffrey J Iliff et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 34(49), 16180-16193 (2014-12-05)
Traumatic brain injury (TBI) is an established risk factor for the early development of dementia, including Alzheimer's disease, and the post-traumatic brain frequently exhibits neurofibrillary tangles comprised of aggregates of the protein tau. We have recently defined a brain-wide network
Shieh-Yueh Yang et al.
Scientific reports, 7(1), 9304-9304 (2017-08-26)
Immunomagnetic reduction (IMR), which involves the use of antibody-functionalized magnetic nanoparticles to specifically label target biomarkers, was utilized to develop an assay for total tau protein in human plasma. The analytic properties of the IMR assay on tau protein were
Ming-Jang Chiu et al.
Frontiers in aging neuroscience, 9, 51-51 (2017-03-23)
Using an ultra-sensitive technique, an immunomagnetic reduction assay, the plasma tau level can be measured to a limit of quantification of pg/ml. In total 126 cognitively normal middle-aged and older adults (45-95 years old) were recruited. The plasma tau levels
Lina Adwan et al.
Journal of neurochemistry, 133(2), 266-272 (2014-10-04)
Tau and its aggregates are linked to the pathology of Alzheimer's disease (AD) and other tauopathies and, therefore, are explored as therapeutic targets for such disorders. Tau belongs to a family of microtubule-associated proteins that promote microtubule assembly. When hyperphosphorylated
Chin-Hsien Lin et al.
Frontiers in aging neuroscience, 10, 123-123 (2018-05-15)
Objective: Parkinson's disease (PD) has significant clinical overlaps with atypical parkinsonism syndromes (APS), which have a poorer treatment response and a more aggressive course than PD. We aimed to identify plasma biomarkers to differentiate PD from APS. Methods: Plasma samples
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service